Stocky turns companies like GENSCRIPT BIO into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. 1548.HK scores 36/100 on Stocky's overall assessment, driven by a weak Growth Compounder Score (34/100) indicating insufficient revenue growth or returns on invested capital to justify equity ownership. Leadership Alignment (45/100) lags healthy benchmarks, suggesting misalignment between founder incentives and shareholder interests. Analyst forecasts diverge too widely for the forward multiple to be meaningful.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for GENSCRIPT BIO:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 36/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates GENSCRIPT BIO (1548.HK) at 36/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. 1548.HK scores 36/100 on Stocky's overall assessment, driven by a weak Growth Compounder Score (34/100) indicating insufficient revenue growth or returns on invested capital to justify equity ownership. Leadership Alignment (45/1
1548.HK's current Stocky Verdict is 36/100, placing it in the "Avoid" band. This composite combines a 34/100 Compounder score, 45/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for GENSCRIPT BIO yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
GENSCRIPT BIO scores 45/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Vulnerability Profile for GENSCRIPT BIO covers customer concentration, supply chain risk, refinancing walls, and regulatory exposure. Not yet finalised.
Sign up free and unlock the full analysis on 1548.HK — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 1548.HK in the app.
